Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries
European Journal of Pharmaceutical Sciences · 2026-12 · 227 · 107652
DOI: 10.1016/j.ejps.2026.107652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmaceutical Sciences, 2026-12. Verfasst von Rasha A Alshaikh und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland. Elec…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms, RNA, Health Services Accessibility. Die Arbeit nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Staatssekretariat für Bildung, Forschung und Innovation, European Commission, UKRI.
Abstract (Originalsprache)
RNA therapies are transforming the treatment landscape for several rare, severe, and previously untreatable diseases. Regulatory approval only permits the medicine to be marketed; it does not determine whether a public health system will fund it. In Europe, this typically relies on national reimbursement bodies, following a Health Technology Assessment (HTA) or comparable processes. Despite the clinical promise of RNA therapeutics, they pose a significant challenge for funding decision makers due to their high costs, limited evidence on long-term effectiveness, and often narrow indications. Therefore, this targeted comparative review was conducted to analyse national HTA decisions and reimbursement policies for selected non-viral RNA therapeutics across six countries: Ireland, England, France, Germany, Canada, and the United States. HTA agencies across the reviewed countries generally issued favourable recommendations for RNA therapeutics reimbursement despite different assessment criteria, citing clinical effectiveness, unmet need, and budget impact as central factors. However, HTA agencies also expressed concerns about long-term benefit, meeting cost-effectiveness thresholds, and limited real-world evidence of these therapeutics. RNA therapeutics were often reimbursed under conditional reimbursement schemes or managed entry pathways. Countries with formal orphan drug pathways or flexible reimbursement mechanisms (e.g. Germany, England) were more likely to facilitate earlier access. With the accelerating growth in new RNA therapeutics, there needs to be consideration of the capacity for, and appropriateness of, current approaches of assessment and reimbursement, as well as the extent to which harmonisation of methods can support equitable and evidence-based patient access across Europe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland. Electronic address: ralshaikh@ucc.ie.
- School of Pharmacy, University College Cork, Cork, Ireland.
- Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
Förderung
- Staatssekretariat für Bildung, Forschung und Innovation
- European Commission
- UKRI
Zitieren
APA
Alshaikh, R. A., Cronin, D. J., Hughes, D. A., & O'Driscoll, C. M. (2026). Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries. European Journal of Pharmaceutical Sciences, 227, 107652. https://doi.org/10.1016/j.ejps.2026.107652
Vancouver
Alshaikh RA, Cronin DJ, Hughes DA, O'Driscoll CM. Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries. European Journal of Pharmaceutical Sciences. 2026;227:107652. doi:10.1016/j.ejps.2026.107652
BibTeX
@article{Alshaikh2026,
author = {Alshaikh, Rasha A and Cronin, Diarmuid J and Hughes, Dyfrig A and O'Driscoll, Caitriona M},
title = {Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries},
journal = {European Journal of Pharmaceutical Sciences},
year = {2026},
volume = {227},
pages = {107652},
doi = {10.1016/j.ejps.2026.107652}
}
EUVIMED